Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 for relapsed or refractory peripheral T-cell lymphoma
CTR20191779Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- May 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in peripheral T-cell lymphoma (PTCL), sponsored by Akeso, Inc.. Started May 2020; status: active.
02
Drugs
cadonilimab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20191779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191779.